Related Experiment Video
Updated: Sep 25, 2026
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Antiplatelet drugs
Graeme J Hankey1, John W Eikelboom
1Royal Perth Hospital, 197 Wellington Street, Perth, WA 6001, Australia. gjhankey@cyllene.uwa.edu.au
Insights
Aspirin and clopidogrel are antiplatelet drugs that prevent vascular events. Combination therapy, especially with glycoprotein IIb/IIIa antagonists, offers additional protection for high-risk cardiovascular patients.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Preventive Cardiology
Background:
- Antiplatelet drugs are crucial for preventing vascular events like myocardial infarction and stroke.
- Aspirin is the first-line treatment, reducing risks by approximately 25% in high-risk individuals.
- Clopidogrel offers an alternative or adjunctive therapy with varying efficacy and cost considerations.
Purpose of the Study:
- To evaluate the comparative effectiveness of antiplatelet agents in secondary cardiovascular prevention.
- To assess the benefits of adding clopidogrel or glycoprotein IIb/IIIa antagonists to aspirin therapy.
- To determine the role of dipyridamole in preventing recurrent stroke.
Main Methods:
- Comparative analysis of clinical trial data on antiplatelet drug efficacy.
- Risk reduction assessment for various antiplatelet regimens in different patient populations.
- Evaluation of safety profiles and cost-effectiveness where applicable.
Main Results:
- Aspirin reduces vascular event risk by ~25%; clopidogrel reduces it by ~10% compared to aspirin.
- Adding clopidogrel to aspirin improves outcomes in acute coronary syndromes and percutaneous coronary intervention.
- Glycoprotein IIb/IIIa inhibitors provide incremental benefits when added to aspirin and clopidogrel in specific scenarios.
Conclusions:
- Aspirin remains a primary agent for secondary cardiovascular prevention.
- Clopidogrel is a valuable alternative for aspirin-intolerant patients or those with recurrent events.
- Combination antiplatelet therapies, including glycoprotein IIb/IIIa inhibitors, enhance protection in high-risk cardiovascular patients.
Abstract:
Antiplatelet drugs protect against myocardial infarction, stroke, cardiovascular death and other serious vascular events in patients with a history of previous vascular events or known risk factors for cardiovascular disease. Aspirin reduces the risk of serious vascular events in patients at high risk of such an event by about a quarter and is recommended as the first-line antiplatelet drug. Clopidogrel reduces the risk of serious vascular events among high-risk patients by about 10% compared with aspirin. It is as safe as aspirin, but much more expensive. It is an appropriate alternative to aspirin for long-term secondary prevention in patients who cannot tolerate aspirin, have experienced a recurrent vascular event while taking aspirin, or are at very high risk of a vascular event (>/= 20% per year). Addition of clopidogrel to aspirin reduces the risk of serious vascular events among patients with non-ST-segment elevation acute coronary syndromes by 20%, and patients undergoing percutaneous coronary intervention by 30%, compared with aspirin alone. Addition of a glycoprotein IIb/IIIa receptor antagonist to aspirin reduces the risk of vascular events among patients with non-ST-segment elevation acute coronary syndromes by 10% and among patients undergoing percutaneous coronary intervention by 30%, compared with aspirin alone; it appears to provide incremental benefit in patients also treated with clopidogrel. Addition of dipyridamole to aspirin seems to be more effective than aspirin alone for preventing recurrent stroke, but its overall effect in preventing serious vascular events in patients with ischaemic stroke and transient ischaemic attack has not been determined.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Peripheral Artery Disease III: Interprofessional Care
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:27Coronary Artery Disease V: Interprofessional Care
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins